4,901 trials
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Orforglipron — 89.9; 79.1 nanogram*hour per milliliter
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970 — 332; 857 nanogram * hour per milliliter (ng*hr/mL
Diabetes Mellitus, Type 2
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug — 1; 0; 0; 0 Participants
Healthy · Obese
Primary: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to…
Asthma
Primary: Area Under the Plasma Concentration-Time Curve (AUC) From Time Zero (Pre-Dose) Extrapolated to Infinite Time (AUC[0-Infinity]) of Depemokimab — 1685.946; 5224.107…
Healthy
Primary: PK: Maximum Observed Concentration (Cmax) of LY3502970 — 80.5; 67.5 nanograms per milliliter (ng/mL)
Erectile Dysfunction
Primary: Number of Participants With Treatment Emergent Serious Adverse Events (TE-SAEs) During the Study Period. — 0; 0 Participants
HIV
Primary: Proportion of Infants Classified as Study Drug-related Safety Failures Through 2 Weeks After DTG-Discontinuation. — 0; 0; 0; 0 proportion of participants
Healthy
Primary: Area Under the Concentration-time Curve of Repaglinide in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 21882.61; 27332.41 hour*picomole/liter
Childhood Apraxia of Speech
Primary: Speech Accuracy of Treated Items — -0.7; 10.6; -2.8; -1.4 percentage of accuracy (change score) — p=0.0001
Healthy · Obese · Overweight
Primary: Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC[0-∞]) of Simvastatin and Its Metabolite Simvastatin Acid Following…
Sickle Cell Disease
Primary: Percentage of Biotin Labeled RBCs — 97.3; 80; 21 percentage of biotin-labeled RBCs
Healthy
Primary: Fraction Excreted in Urine as Percentage of the Administered Dose Over the Time Interval From 0 to the Last Quantifiable Time Point (fe Urine,0-tz) of…
Colorectal Adenocarcinoma · Metastatic Pancreatic Adenocarcinoma · Recurrent Colorectal Carcinoma
Primary: Recommended Phase II Dose of the Combination of XL888 and Pembrolizumab as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events Version…
Healthy
Primary: SRD Part - Number of Subjects With Drug-related Adverse Events — 0; 0; 0; 0 Participants